Search

Your search keyword '"Theodoros Vasilakopoulos"' showing total 3 results
Start Over Author "Theodoros Vasilakopoulos"
3 results on '"Theodoros Vasilakopoulos"'

1. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

Author

Agnes Nagy, Rene-Olivier Casasnovas, Sameer Bakhshi, Sharon Shacham, Juan-Manuel Sancho, Ronit Gurion, Josée M. Zijlstra, Jatin P. Shah, Miklos Egyed, Brian T. Hill, Krzysztof Warzocha, Gabriel Tremblay, Michael W. Schuster, Fritz Offner, Reda Bouabdallah, Dimitrios Tomaras, Paolo Caimi, Andre Goy, Priyanka Samal, Catherine Thieblemont, Joost S.P. Vermaat, Matthew Ku, Ulrich Jäger, John Kuruvilla, Nagesh Kalakonda, George A Follows, Eric Van Den Neste, Miguel Ángel Canales Albendea, Michael Kauffman, Nada Hamad, Fatima De la Cruz, Patrick Daniele, Marie Maerevoet, Theodoros Vasilakopoulos, Federica Cavallo, Sylvain Choquet, Karyopharm Therapeutics Inc., Newton, MA, U918, Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institut Jules Bordet [Bruxelles], Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Amsterdam UMC, Addenbrooke's Hospital, Cambridge University NHS Trust, Leiden University Medical Center (LUMC), Institute of Translational Medicine, University of Liverpool, Hackensack University Medical Center [Hackensack], Service d'Hématologie clinique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Catholique de Louvain = Catholic University of Louvain (UCL), Cleveland Clinic, Service d'Hémato-oncologie [CHU Saint-Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Turin, Hospital Universitario Virgen del Rocío [Sevilla], University Health Network, St Vincent's Hospital Melbourne [Australia], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Medizinische Universität Wien = Medical University of Vienna, University Hospitals Case Medical Center, Tel Aviv University [Tel Aviv], Institute of Hematology and Transfusion Medicine[Warsaw, Poland] (IHTM), Germans Trias i Pujol Hospital, Barcelona Autonomous University, Stony Brook University [SUNY] (SBU), State University of New York (SUNY), Ghent University Hospital, National and Kapodistrian University of Athens (NKUA), Semmelweis University [Budapest], Hospital Universitario La Paz, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, and UCL - (SLuc) Service d'hématologie

Subjects
Male, Oncology, Cancer Research, Health utility, FACT-Lym, patient reported outcomes, MESH: Patient Reported Outcome Measures, MESH: Aged, 80 and over, 0302 clinical medicine, Quality of life, Recurrence, Medicine and Health Sciences, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, health, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, General Medicine, Middle Aged, MESH: Drug Resistance, Neoplasm, 3. Good health, health-related quality of life, Hydrazines, EQ-5D-5L, patient-reported outcomes, 030220 oncology & carcinogenesis, Female, health utility, Lymphoma, Large B-Cell, Diffuse, MESH: Hydrazines, Adult, disutility of adverse events, medicine.medical_specialty, diffuse large B-cell lymphoma, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Refractory, Internal medicine, medicine, Humans, health state utility, selinexor, Patient Reported Outcome Measures, Aged, Health related quality of life, MESH: Humans, business.industry, MESH: Quality of Life, MESH: Adult, Triazoles, medicine.disease, MESH: Male, MESH: Recurrence, Lymphoma, MESH: Triazoles, utility, Drug Resistance, Neoplasm, Relapsed refractory, Quality of Life, MESH: Lymphoma, Large B-Cell, Diffuse, business, MESH: Female, Diffuse large B-cell lymphoma, Progressive disease, 030215 immunology
Abstract

Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT - Lymphoma (p = 3 adverse events and serious adverse events were not associated with clinically meaningful negative QoL impacts.

Published
2021
Full Text
View/download PDF

2. PCN325 Health Utility in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) Patients - Results of a Phase II Trial with ORAL Selinexor

Author

R. Bouabdallah, Marie Maerevoet, George A. Follows, M. A. Canales Albendea, Michael W. Schuster, John Kuruvilla, Theodoros Vasilakopoulos, Juan-Manuel Sancho, Joost S.P. Vermaat, Ronit Gurion, Miklos Egyed, Nagesh Kalakonda, Ulrich Jaeger, Patrick Daniele, Matthew Ku, Catherine Thieblemont, Priyanka Samal, Paolo Caimi, F. de la Cruz, Fritz Offner, E. Van Den Neste, Josee M. Zijlstra, Andre Goy, René-Olivier Casasnovas, Brian T. Hill, Nada Hamad, Sylvain Choquet, Gabriel Tremblay, Sameer Bakhshi, Federica Cavallo, Krzysztof Warzocha, and Ágnes Nagy

Subjects
Oncology, medicine.medical_specialty, Health utility, business.industry, Health Policy, Internal medicine, Relapsed refractory, Public Health, Environmental and Occupational Health, Medicine, business, medicine.disease, Diffuse large B-cell lymphoma
Published
2020
Full Text
View/download PDF

3. Exposure to cigarette smoke abrogates the beneficial effect of ischemic postconditioning

Author

Spyros Zakynthinos, Ioanna Andreadou, Efstathios K. Iliodromitis, Constantinos Glynos, Andreas Papapetropoulos, Athanasia Chatzianastasiou, Sofia-Iris Bibli, Theodoros Vasilakopoulos, and Dimitris Toumpanakis

Subjects
0301 basic medicine, Male, Physiology, Myocardial Infarction, Infarction, Blood Pressure, 030204 cardiovascular system & hematology, medicine.disease_cause, chemistry.chemical_compound, Mice, 0302 clinical medicine, Enos, Smoke, Medicine, Myocardial infarction, Ischemic Postconditioning, Cyclic GMP, biology, Reverse Transcriptase Polymerase Chain Reaction, Anesthesia, Hypertension, Ischemic Preconditioning, Myocardial, Tumor necrosis factor alpha, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, Nitric Oxide Synthase Type III, Blotting, Western, Cardiomegaly, Myocardial Reperfusion Injury, Endothelial NOS, Nitric oxide, 03 medical and health sciences, Physiology (medical), Internal medicine, Tobacco, Animals, RNA, Messenger, Protein kinase B, business.industry, Interleukin-6, Tumor Necrosis Factor-alpha, Myocardium, medicine.disease, biology.organism_classification, Disease Models, Animal, Oxidative Stress, 030104 developmental biology, Endocrinology, chemistry, business, Proto-Oncogene Proteins c-akt, Oxidative stress
Abstract

Cigarette smoking is one of the risk factors for coronary artery disease. Although conditioning decreases infarct size in hearts from healthy animals, comorbidities may render it ineffective. We investigated the effects of cigarette smoke (CS) exposure on intracellular myocardial signaling, infarct size after ischemia-reperfusion, and the potential interference with ischemic conditioning. Exposure of mice to CS increased blood pressure, caused cardiac hypertrophy, and upregulated the nitric oxide synthatse (NOS)/soluble guanylate cyclase (sGC)/cGMP pathway. To test the effect of CS exposure on the endogenous cardioprotective mechanisms, mice were subjected to regional myocardial ischemia and reperfusion with no further intervention or application of preconditioning (PreC) or postconditioning (PostC). Exposure to CS did not increase the infarction compared with the room air (RA)-exposed group. PreC was beneficial for both CS and RA vs. nonconditioned animals. PostC was effective only in RA animals, while the infarct size-limiting effect was not preserved in the CS group. Differences in oxidative stress markers, Akt, and endothelial NOS phosphorylation and cGMP levels were observed between RA and CS groups subjected to PostC. In conclusion, exposure to CS does not per se increase infarct size. The beneficial effect of ischemic PreC is preserved in mice exposed to CS, as it does not affect the cardioprotective signaling; in contrast, PostC fails to protect CS-exposed mice due to impaired activation of the Akt/eNOS/cGMP axis that occurs in parallel to enhanced oxidative stress.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results